Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)

NCT00557193 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00557193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00557193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
January 15, 2008
Completion date
June 30, 2024
Enrollment
218 (actual)
Sites
170

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute undifferentiated leukemia, childhood t acute lymphoblastic leukemia